Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus

Joy Cuthberston, Steven Patterson, Finbarr O'Harte, Patrick Bell

Research output: Contribution to journalArticle

Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by rapid inactivation by the enzyme dipeptidylpeptidase-4 (DPP-4). Metformin has been reported to inhibit DPP-4. Here we investigated the acute effects of metformin and GLP-1 alone or in combination on plasma DPP-4 activity, active GLP-1 concentrations, and glucose lowering in type 2 diabetes mellitus.
Original languageEnglish
Pages (from-to)52-56
Number of pages5
JournalMetabolism
Volume60
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Glucagon-Like Peptide 1
Metformin
Type 2 Diabetes Mellitus
Glucose
Serum
Incretins
Meals
Blood Glucose
Hormones
Enzymes
Therapeutics

Cite this

@article{2450e044474447c1908b46a65fa67a64,
title = "Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus",
abstract = "Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by rapid inactivation by the enzyme dipeptidylpeptidase-4 (DPP-4). Metformin has been reported to inhibit DPP-4. Here we investigated the acute effects of metformin and GLP-1 alone or in combination on plasma DPP-4 activity, active GLP-1 concentrations, and glucose lowering in type 2 diabetes mellitus.",
author = "Joy Cuthberston and Steven Patterson and Finbarr O'Harte and Patrick Bell",
year = "2011",
month = "1",
doi = "10.1016/j.metabol.2010.01.001",
language = "English",
volume = "60",
pages = "52--56",
journal = "Metabolism",
issn = "0026-0495",
publisher = "Elsevier B.V.",
number = "1",

}

Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. / Cuthberston, Joy; Patterson, Steven; O'Harte, Finbarr; Bell, Patrick .

In: Metabolism , Vol. 60, No. 1, 01.2011, p. 52-56.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus

AU - Cuthberston, Joy

AU - Patterson, Steven

AU - O'Harte, Finbarr

AU - Bell, Patrick

PY - 2011/1

Y1 - 2011/1

N2 - Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by rapid inactivation by the enzyme dipeptidylpeptidase-4 (DPP-4). Metformin has been reported to inhibit DPP-4. Here we investigated the acute effects of metformin and GLP-1 alone or in combination on plasma DPP-4 activity, active GLP-1 concentrations, and glucose lowering in type 2 diabetes mellitus.

AB - Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by rapid inactivation by the enzyme dipeptidylpeptidase-4 (DPP-4). Metformin has been reported to inhibit DPP-4. Here we investigated the acute effects of metformin and GLP-1 alone or in combination on plasma DPP-4 activity, active GLP-1 concentrations, and glucose lowering in type 2 diabetes mellitus.

U2 - 10.1016/j.metabol.2010.01.001

DO - 10.1016/j.metabol.2010.01.001

M3 - Article

VL - 60

SP - 52

EP - 56

JO - Metabolism

JF - Metabolism

SN - 0026-0495

IS - 1

ER -